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Abstract Lytic bone diseases and in particular osteoporosis
are common age-related diseases characterized by enhanced
bone fragility due to loss of bone density. Increasingly,
osteoporosis poses a major global health-care problem due
to the growth of the elderly population. Recently, it was
found that the gene regulatory transcription factor CCAAT/
enhancer binding protein beta (C/EBPβ) is involved in
bone metabolism. C/EBPβ occurs as different protein
isoforms of variable amino terminal length, and regulation
of the C/EBPβ isoform ratio balance was found to represent
an important factor in osteoclast differentiation and bone
homeostasis. Interestingly, adjustment of the C/EBPβ iso-
form ratio by the process of translational control is
downstream of the mammalian target of rapamycin kinase
(mTOR), a sensor of the nutritional status and a target of
immunosuppressive and anticancer drugs. The findings
imply that modulating the process of translational control
of C/EBPβ isoform expression could represent a novel
therapeutic approach in osteolytic bone diseases, including




Regulating bone mass, bone turnover (remodeling), and
bone integrity requires a tight coupling between the two
major bone cell types, the bone-forming osteoblasts, and
the bone-resorbing osteoclasts [1]. Maintenance of a correct
balance between the functions of both cell types is crucial
during the phase of skeletal development and retaining
bone homeostasis during adulthood. Pathological bone loss
may occur when the cross talk between osteoblasts and
osteoclasts is disturbed. This is often due to increased
osteoclastic activity and diminished osteoblast activity, as
observed in age-related and secondary osteoporosis or in
inflammation-induced(e.g.,inrheumatoidarthritis)orcancer-
induced bone loss (reviewed in [2]). Although therapeutic
strategies to treat osteoporosis have been developed, increas-
ing knowledge on the regulation of osteoclastogenesis may
facilitate identification of novel therapeutic targets and
rational approaches.
Recently, a novel player in the regulation of osteoclast
differentiation has been identified as the transcription factor
CCAAT/enhancer binding protein beta (C/EBPβ)[ 3].
C/EBPβ was found to affect both osteoblast activity in bone
formation and osteoclast activity in bone resorption. These
insights were obtained by combining studies of recombinant
genetic mouse models and cell biological, pharmacological,
and gene expression-profiling approaches. Briefly, the
distinct C/EBPβ isoforms were found to differentially
regulate expression of the downstream transcription factor
MafB that acts like a brake to restrict osteoclastic differen-
tiation and osteolytic activity [4]. C/EBPβ is normally
expressed as two long transactivator isoforms, termed
“LAP*/LAP” or as a truncated repressor, termed “LIP”
(for the sake of simplicity, we will not discriminate between
both activator isoforms, although LAP* displays additional
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DOI 10.1007/s00109-009-0567-8epigenetic features in comparison to LAP). The balance
between LAP*/LAP and LIP is adjusted by the mammalian
target of rapamycin kinase (mTOR) pathway, which acts as
a sensor to integrate growth and nutrient stimuli. The LAP
C/EBPβ isoform enhances expression of MafB that
subsequently blunts osteoclastogenesis, whereas the trun-
cated LIP C/EBPβ isoform enhances osteoclastogenesis by
decreasing expression of MafB [3].
C/EBPβ
The transcription factor C/EBPβ belongs to the gene
regulator family of the CCAAT/enhancer binding proteins,
which consists of six members: α, β, δ, γ, ε, and ζ. C/EBPs
are characterized by highly conserved carboxyl terminal
“basic leucine zipper domains” (bZip), containing an alpha
helical basic DNA binding domain and a leucine zipper
coiled-coil dimerization domain. The N-terminal domains of
C/EBPs are more variable and only partially conserved. The
two main members C/EBPα and C/EBPβ are partially
redundant during embryogenesis, and after birth, are
involved in cell growth, proliferation, and differentiation in
several tissues [5]. Both C/EBPα and C/EBPβ are encoded
by intronless genes and are present as single messenger
RNAs (mRNAs). Nevertheless, amino terminally truncated
protein isoforms may be generated by a process known as
alternative translation initiation [6]. Thus, the protein
isoforms display different domains and exert distinct
biological functions [7].
Alternative initiation of C/EBP translation is mediated
by small “upstream open reading frames” (uORF) that act
as regulatory elements to sense the activity of the
translation machinery and to direct initiation to alternative
start codons. A key signaling component of regulated
translational initiation is the mTOR. The activity of mTOR
depends on nutritional signals, including glucose and amino
acid availability, and it also responds to extracellular signals
such as growth factors and insulin [8]. The macrolide
antibiotic rapamycin specifically inhibits the mTOR kinase,
lowering the activity of the critical eukaryotic translation
initiation factor 4E (eIF4E). Low eIF4E activity abolishes
translation reinitiation, and in the case of C/EBPβ,
diminishes expression of LIP. This results in a higher
LAP to LIP ratio of the C/EBPβ isoforms and alters
expression of C/EBPβ target genes (Fig. 1)[ 6].
C/EBPβ is involved in the differentiation of a large
variety of cell types, including keratinocytes, hepatocytes,
mammary epithelial cells, ovarian luteal cells, adipocytes, B
cells, and macrophages. Moreover, C/EBPβ regulates cell
survival, apoptosis, metabolism, inflammation, and tumor-
igenic transformation [5, 7, 9]. C/EBPβ is expressed as
three different protein isoforms differing in their N-terminal
domains, LAP*, LAP (both are transcriptional activators),
and LIP (a transdominant repressor), each displaying
unique functions in various cellular processes. The diversity
of C/EBPβ’s functional properties is further increased by
signaling-dependent posttranslational modifications that
regulate the biological activity and the subcellular distribu-
tion of C/EBPβ [7]. Action of C/EBPβ requires dimeriza-
tion through the bZip domain, either with another C/EBPβ
molecule or through heterodimerization with any of the
other C/EBP family members or some transcription factors
with compatible bZip domains.
C/EBPβ controls bone cells
C/EBPβ has been suggested to act as a scaffold protein in
the assembly of osteogenic transcription factors [9], such as
with Runx2 or ATF4, thereby enhancing osteoblast differ-
entiation [10, 11]. Analyses of C/EBPβ-deficient mice
confirmed a role of C/EBPβ in osteoblast differentiation
and bone formation: In the absence of C/EBPβ, bone mass
is decreased [12] due to decreased osteoblast differentiation
Fig. 1 Translational control and C/EBPβ isoform regulation. Growth
factor, hormone, nutrition, and stress signals are integrated by the
mammalian mTOR kinase that monitors the growth and differentiation
status of a cell. The mTOR kinase (low activity (blue); high activity
(red)) regulates the function of the translation initiation machinery.
The cis-regulatory upstream open reading frame uORF in the C/EBPβ
mRNA senses the activity of the translation machinery and directs
initiation, leaky scanning, and reinitiation. High activity of the
translation machinery directs reinitiation and production of the
truncated “repressor” isoform LIP of C/EBPβ. Lowering the activity
of the initiation machinery results in leaky scanning over the uORF
ATG and translation initiation at the first ATG, resulting in the
production of the long “activator” isoform LAP. Rapamycin inhibits
mTOR signaling, resulting in the production of mainly the LAP
isoform
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noncell autonomous effects [3, 13]. C/EBPβ deficiency
also resulted in growth retardation during embryogenesis
[11, 14] and at postnatal stages [3], due to diminished
chondrocyte differentiation [11, 14]. C/EBPβ activates the
cyclin-dependent kinase inhibitor p57
kip in chondrocytes
that restricts chondrocyte proliferation and stimulates the
transition to hypertrophic differentiation [14].
Surprisingly, expression of the (repressor) LIP isoform
instead of the entire C/EBPβ gene from its endogenous
locus in “knock-in” mouse mutants restored bone formation
and rescued the growth retardation observed in C/EBPβ-
deficient animals [3]. Moreover, LIP enhanced osteoblast
differentiation and function [3], possibly by acting as a
coactivator for Runx2 [10].
Besides cell autonomous effects, C/EBPβ is possibly
also involved in paracrine action and the coupling between
osteoblasts and osteoclasts. C/EBPβ and its related family
member C/EBPδ induce IGF-I expression [15–18] that
represents an important anabolic factor for bone formation.
Similar to TGFβ [19], IGF-I is released from the bone
matrix by osteoclasts and may then stimulate osteoblasts
[20]. In addition, coupling between osteoclasts and osteo-
blasts is thought to involve the cytokines interleukin 6 (IL-
6) and tumor necrosis factor alpha (TNFα)[ 20] that also
represent targets of C/EBPβ in osteoclasts [3].
C/EBPβ as a switch in osteoclast differentiation
The first observations suggesting a connection between
C/EBPβ and osteoporosis were made over a decade ago in
connection with the cytokine IL6. C/EBPβ, in synergy with
NFκB, was found to act downstream of estrogen, involving
binding of the estrogen receptor and resulting in suppres-
sion of IL6 gene transcription in osteoblasts [21]. This is of
clinical relevance as decreased estrogen levels are one of
the major causes of postmenopausal osteoporosis, which
results in increased IL-6 that activates osteoclasts and thus
bone resorption [22, 23]. Indeed, C/EBPβ-deficient mice
show a similar general pathology as mice overexpressing
IL6 [24] and with bone loss as a consequence of enhanced
activity of osteoclasts [3]. Macrophage defects observed in
C/EBPβ-deficient mice [25] were the first indication of a
possible role of C/EBPβ in the bone-resorbing osteoclast,
which shares a monocytic precursor cell with macrophages.
In contrast to macrophages, osteoclast precursors fuse into
large polykaryons to generate matureosteoclasts that attach to
the bone surface and resorb bone matrix. Both differentiation
and osteolytic activity of osteoclasts requires macrophage
colony-stimulating factor (M-CSF) and membrane-bound
receptor activator of NFκB ligand (RANK-L), which are both
producedbyosteoblasts andbystromal cells.Osteoblasts also
produce osteoprotegerin, a decoy receptor of RANK-L,
thereby counteracting and fine tuning the effect of RANK-L
in osteoclastogenesis. These cytokines activate downstream
osteoclastic transcription factors, including NFATc1, Mitf,
andc-Fosthataffectproliferation,differentiation,andsurvival
of osteoclasts [2, 26].
Absence of C/EBPβ or expression of only the LIP
isoform was observed to strongly enhance osteoclast
differentiation. This suggested that the absence of LAP
would cause enhanced osteoclastogenesis, and LAP would
induce a gene whose product blocks osteoclast differenti-
ation. Such an inhibitor was identified as MafB, a
transcription factor recently found to be involved in
osteoclastogenesis [4] and a target gene of LAP [3].
MafB is also a bZIP transcription factor that, however,
belongs to a distinct family. MafB is important in several
developmental processes [27] and in oncogenesis [28]. In
the hematopoietic system, the function of MafB is restricted
to the monocytic lineage [29]. Similarly to C/EBPβ, the
expression of MafB starts at the myeloblast stage and
strongly increases during macrophage differentiation [29].
Although not strictly required for macrophage differentia-
tion, absence of MafB in monocytes results in an altered
phenotype. Absence of MafB reduces F4/80 levels in
macrophages [30]. Upon M-CSF treatment, MafB-deficient
macrophages form multiple extensive cellular extrusions,
often branched, known as filopodia [31], a process that also
occurs in osteoclasts and that is required for cell migration
[32].
MafB directs macrophage versus osteoclast differentia-
tion [4], and recently, MafB was reported to restrict M-CSF
receptor-induced activation of the PU.1 gene [33] that
encodes an early and essential myeloid and osteoclastic
transcription factor [26]. No bone phenotype has been
reported of MafB knockout mice so far, possibly due to
their early postnatal lethality [27]. However, the MafB
protein interacts with and thereby attenuates the activity of
the osteoclastogenic transcription factors NFATc1, Mitf,
and c-Fos [4]. The long C/EBPβ isoform LAP induces
MafB expression and thus inhibits osteoclastogenesis,
whereas absence of LAP (such as in C/EBPβ-deficient
animals or in knockin mutants expressing only the
inhibitory LIP isoform) results in diminished MafB expres-
sion. Lack of MafB enhances the functionality of NFATc1,
its downstream target OSCAR, and probably other factors,
including Mitf and c-Fos, to augment expression of
osteoclast genes, including the cell fusion-promoting genes
DC-STAMP, ATP6v0d2, and TNFα [34]. The opposing
roles of the different C/EBPβ protein isoforms in MafB
expression suggest that the C/EBPβ isoform ratio plays a
fundamental role as an upstream regulator in the initiation
of osteoclastogenesis and connects MafB expression and
osteoclastogenesis to the mTOR pathway (Fig. 2).
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Therapies of osteoporosis concentrate on the inhibition of
the pathological bone resorption by osteoclasts using
mainly bisphosphonates, but also estrogen-like drugs such
as raloxifene, or strontium ranelate [1, 2, 35]. However,
bisphosphonates inhibit the bone remodeling cycle, raising
the need for the development of shorter-acting resorption
inhibitors, which will not affect the bone-remodeling
process itself too much to ensure continuous repair of
Fig. 2 C/EBPβ as a master switch in osteoclast differentiation. a The
LAP isoform of C/EBPβ induces expression of MafB. MafB binds to
and inactivates the osteoclastic transcription factors c-Fos, Mitf, and
NFATc1. Inactivation of these key transcription factors prevents
osteoclast differentiation by inhibition of osteoclast target gene
expression of OSCAR and NFATc1, resulting in inhibition of NFATc1
target genes, including the cell fusion genes DC-STAMP, ATP6v0d2,
and TNFα (partially derived from [4, 34]). b The LIP isoform of
C/EBPβ inhibits MafB expression. As a result, MafB becomes
limiting, and lack of MafB permits access of the osteoclast
transcription factors (often in conjunction with NFATc1 as a major
osteoclast transcription factor) to activate target genes and osteoclast
differentiation
Fig. 3 Dual effect of rapamycin
on cancer-induced bone loss. a
In this hypothetical model,
several types of tumor cells with
high LIP expression (breast,
prostate, lung, multiple
myeloma) preferentially
generate osteolytic metastasis by
activating osteoclasts to release
tumor-promoting growth factors
(e.g., TGFβ, IGF-I). This results
in a continuous cycle of stimu-
lation of metastatic cells and
bone resorption (derived from
[56]). b The vicious circle
between tumor and stroma
(osteoclasts) may be interrupted
by drugs that impinge on
translational control, such as
rapamycin or its derivatives
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skeleton [2]. Therefore, novel therapeutic strategies are
required to improve treatment strategies in osteoporosis and
other lytic bone diseases. The findings of involvement of
translational control of C/EBPβ isoforms in directing
osteoclastogenesis may entail such novel targets for
therapy. Translational control is affected by the antibiotic
rapamycin that specifically inhibits mTOR signaling,
resulting in a shift of the C/EBPβ isoform ratio toward
the LAP isoform (Fig. 1). Rapamycin treatment thus favors
LAP expression over LIP, which results in enhanced MafB
gene activation and thus inhibition of both osteoclasto-
genesis and bone resorption. Inhibition of mTOR by
rapamycin inhibits osteoclastogenesis not only in mouse
[3, 36] but also in human cells [37], suggesting that the
murine model may provide disease relevant data. Impor-
tantly, a derivative of rapamycin has already been shown to
inhibit bone loss in an experimental rat model, where
osteoporosis was induced by ovariectomy [37]. So far,
however, no clinical data is available concerning the impact
of rapamycin on bone. Taken together, these data suggest
that rapamycin could potentially serve as a therapeutic
agent in treating osteolytic diseases [38].
The mTOR signaling pathway is also important in the
regulation of autophagy, a process recently proposed to be
involved in osteoclast function [39, 40]. Rapamycin
induces autophagy and therefore might play a role in late
osteoclastogenesis. This would be in addition to the action
of rapamycin early in osteoclast differentiation, where it
inhibits differentiation [3]. Autophagy was suggested to
decelerate aging processes [41], as also recently found for
rapamycin that extends the life span of aged mice [42]. This
may suggest that dampening mTOR signaling prevents age-
related disease progression, including cancer.
Along these lines, the LIP isoform has been associated
with enhanced proliferation of multiple myeloma and breast
cancer and in Hodgkin and anaplastic large cell lymphoma.
A rapamycin derivative was demonstrated to decrease
tumor cell proliferation by abrogating LIP expression
[43]. These observations further strengthen the notion that
C/EBPβ is an important downstream target of mTOR,
affecting cell proliferation and differentiation in diverse cell
types. Moreover, rapamycin has been shown to inhibit
tumor cell metastasis in an osteosarcoma mouse model
[44]. Rapamycin has already been considered as a novel
treatment in multiple myeloma, where it restrains tumor cell
proliferation [45] and has antitumor activity, as reported in
breast cancer patients where rapamycin was tested in
clinical phase trials [46]. Induction of autophagy by
rapamycin would, in addition, sensitize cancer cells to
complementary treatments [47]. Both multiple myeloma
and breast cancer generate bone metastases, causing local
osteolytic lesions [48, 49]. Also, in rheumatoid arthritis,
local bone loss occurs, and rapamycin was found to be
beneficial due to its immunosuppressant characteristics [50,
51]. The observation that rapamycin also functions as an
antiresorptive agent by modulating the C/EBPβ isoform
ratio [3] may suggest a bipartite function [52] as tumor
suppressor or immune suppressant and as an osteoclast
regulator, as depicted in Fig. 3.
Rapamycin’s immunosuppressant action due to modulation
of regulatory Tcells might raise concerns when used for other
purposes than immunosuppression, e.g., as in cancer patients
or elderly with osteolytic diseases. Problems in wound healing
[53] and occurrence of anemia [54] have been reported,
although no increase in infectious complications are also
reported [55].
It is interesting to note that the downstream C/EBPβ target
MafB has also been found to be deregulated in the majority of
multiple myeloma cases [28]. Moreover, C/EBPβ is known
to play a central role in inflammation. Both processes have a
strong impact on osteoclastogenesis and can induce patho-
logical bone resorption. The recent identification of the role
of the C/EBPβ isoform ratio in the control of osteoclast
differentiation and bone resorption may link the pathology of
these lytic bone diseases to the translational control of a
distinct gene regulator and may thus open new avenues for
novel therapeutic approaches.
The usage of rapamycin to direct translational control
might have several potential benefits to treat osteolytic-
associated diseases, as it can attack these diseases at different
levels. Rapamycin treatment, combined with restraining
osteoclast differentiation, may have combinatorial functions
in treating osteolytic diseases. However, one has to take into
consideration that inhibition of the mTOR pathway could
have adverse side effects, requiring the development of novel
rapamycin analogs or novel tissue-specific mTOR inhibitors
displaying less side effects.
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